Table 1: Characteristics of studies included in the meta-analysis.

Study Title, Author, and Year of Publication

Population and Study Design



Outcomes Measured

Follow-up Duration


Evaluation of Bromocriptine in the treatment of acute severe peripartum cardiomyopathy


Sliwa, et al. [16]



Total N = 20 patients


Mean Age: 26 8



NYHA fc II: 50%

NYHA fc III/IV: 50%



Baseline LVEF (%): 27 7.9



Randomized Controlled Trial



Group A (10 patients)

Standard HF Therapy:

Carvedilol 6.25 mg - 12.5 mg BID;

Enalapril 5 mg - 10 mg OD;

Furosemide 80 mg - 120 mg OD



Group B (10 patients)

Bromocriptine 2.5 mg BID 2 weeks then OD 6 weeks on top of Standard HF therapy



        Cardiovascular Mortality


        Left Ventricular Ejection Fraction


        Worsening NYHA functional class III / IV


        6 months



Bromocriptine in management of peripartum cardiomyopathy: A randomized study on 96 women in Burkina Faso.



Yameogo, et al. [17]





Total N = 96 patients


Mean Age: 29.4 3.4



NYHA fc III: 28.12%

NYHA fc IV: 71.88%



Baseline LVEF (%): 36.4 5.5


Randomized Controlled Trial



Group A (48 patients):

Standard HF therapy:

Captopril 6.25 mg - 25 mg OD

Furosemide 80 mg OD



Group B (48 patients):

Bromocriptine 2.5 mg BID 4 weeks on top of standard HF therapy



        Cardiovascular Mortality


        Echocardiographic parameters:




        Change in dyspnea


        2 weeks


        1 month


        3 months


        6 months


        12 months
























HF: Heart Failure; LVEF: Left Ventricular Ejection Fraction; NYHA: New York Heart Functional Class; LVEDD: Left Ventricular End Diastolic Diameter;

LVESD: Left Ventricular End Diastolic Diameter; TAPSE: Tricuspid Annular Plane Systolic Excursion.